Overview

Post-Exposure Prophylaxis in Health Care Workers

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Objective: The objective of this study is to determine the safety and tolerability of Post-exposure Prophylaxis (PEP) with a regimen of Truvada + Kaletra among health care workers (HCWs) at Henry Ford Hospital. Hypothesis: Raltegravir is safe and better tolerated compared with Kaletra, each in combination with Truvada, as assessed by review of completion rates of PEP and also review of completed safety data.
Phase:
Phase 4
Details
Lead Sponsor:
Henry Ford Health System
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Lopinavir
Raltegravir Potassium
Tenofovir